DBV Technologies is progressing from a development-centric biotech into a commercial-stage player with promising clinical results for its Viaskin Peanut patch, notably the Phase 3 VITESSE trial. Despite no operating revenues from product sales, the company has ramped R&D and sales readiness expenses considerably. Supported by significant equity financings and manufacturing agreements, DBV prepares for potential U.S. and European market entry. However, its high cash burn, net losses, and need for ongoing capital injections underscore execution risks in this crucial transition period.